Auswahl der wissenschaftlichen Literatur zum Thema „Y220C“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Inhaltsverzeichnis
Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "Y220C" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Zeitschriftenartikel zum Thema "Y220C"
Gener-Ricos, Georgina, Jan Philipp Bewersdorf, Sanam Loghavi, Aaron D. Goldberg, Christopher Famulare, Ghayas C. Issa, Gautam Borthakur et al. „TP53 Y220C Mutations in Patients with Myeloid Malignancies“. Blood 142, Supplement 1 (28.11.2023): 1477. http://dx.doi.org/10.1182/blood-2023-189343.
Der volle Inhalt der QuelleCarter, Bing Z., Po Yee Mak, Baozhen Ke, Yuki Nishida, Steffen Boettcher, Andrea Bedoy, Lauren B. Ostermann et al. „Selective Targeting of TP53-Y220C Mutant AML By PC14586 Results in TP53 Wild-Type Conformation and Synergistical Apoptosis Induction By Concomitant Inhibition of Xpo-1, MDM2, or Bcl-2“. Blood 142, Supplement 1 (28.11.2023): 2261. http://dx.doi.org/10.1182/blood-2023-181186.
Der volle Inhalt der QuellePuzio-Kuter, Anna M., Chris Mulligan, Brandon Russo, Amy Wiebesiek, Lizhong Xu, Hong Yang, Binh Vu und Melissa Dumble. „Abstract 1295: Small molecule reactivators of Y220C mutant p53 modulate tumor infiltrating leukocytes and synergize with immune checkpoint inhibitors“. Cancer Research 82, Nr. 12_Supplement (15.06.2022): 1295. http://dx.doi.org/10.1158/1538-7445.am2022-1295.
Der volle Inhalt der QuelleZheng, Qian, Peng Wang, Chen Liang, Yao Li, Xin Sun, Amin Li, Wei Zhang, Wei Long und Yanping Wang. „Abstract 5940: JAB-30355: A highly potent, orally bioavailable p53-Y220C reactivator“. Cancer Research 84, Nr. 6_Supplement (22.03.2024): 5940. http://dx.doi.org/10.1158/1538-7445.am2024-5940.
Der volle Inhalt der QuelleLiu, Meng, Kaijun Geng, Biao Lu, Yuanfeng Xia und Fanglong Yang. „Abstract 7275: GS-P-328, a brain-penetrant small molecule p53 Y220C reactivator for tumors harboring p53 Y220C mutation“. Cancer Research 84, Nr. 6_Supplement (22.03.2024): 7275. http://dx.doi.org/10.1158/1538-7445.am2024-7275.
Der volle Inhalt der QuelleValenzuela-Chavira, Ignacio, Salvador Meneses-Sagrero, Aldo A. Arvizu-Flores, Javier Hernández-Paredes, Luisa Rascón-Valenzuela, Carlos A. Velázquez-Contreras und Ramón E. Robles-Zepeda. „Molecular Docking of the Cardenolides of Asclepias subulata in the Human p53 Protein Reveals an Interaction in the Cleft of the Y220C Mutant“. Current Chemical Biology 15, Nr. 3 (September 2021): 222–33. http://dx.doi.org/10.2174/2212796815666211026112056.
Der volle Inhalt der QuelleBauer, Matthias R., Rhiannon N. Jones, Raysa K. Tareque, Bradley Springett, Felix A. Dingler, Lorena Verduci, Ketan J. Patel, Alan R. Fersht, Andreas C. Joerger und John Spencer. „A structure-guided molecular chaperone approach for restoring the transcriptional activity of the p53 cancer mutant Y220C“. Future Medicinal Chemistry 11, Nr. 19 (Oktober 2019): 2491–504. http://dx.doi.org/10.4155/fmc-2019-0181.
Der volle Inhalt der QuelleBaud, Matthias G. J., Matthias R. Bauer, Lorena Verduci, Felix A. Dingler, Ketan J. Patel, Deeptee Horil Roy, Andreas C. Joerger und Alan R. Fersht. „Aminobenzothiazole derivatives stabilize the thermolabile p53 cancer mutant Y220C and show anticancer activity in p53-Y220C cell lines“. European Journal of Medicinal Chemistry 152 (Mai 2018): 101–14. http://dx.doi.org/10.1016/j.ejmech.2018.04.035.
Der volle Inhalt der QuelleSchram, Alison M., Geoffrey I. Shapiro, Melissa L. Johnson, Anthony W. Tolcher, John A. Thompson, Anthony B. El-Khoueiry, Andrae L. Vandross et al. „Abstract LB_A25: Updated Phase 1 results from the PYNNACLE Phase 1/2 study of PC14586, a selective p53 reactivator, in patients with advanced solid tumors harboring a TP53 Y220C mutation“. Molecular Cancer Therapeutics 22, Nr. 12_Supplement (01.12.2023): LB_A25. http://dx.doi.org/10.1158/1535-7163.targ-23-lb_a25.
Der volle Inhalt der QuelleLane, David P., und Chandra S. Verma. „Covalent Rescue of Mutant p53“. Cancer Discovery 13, Nr. 1 (09.01.2023): 14–16. http://dx.doi.org/10.1158/2159-8290.cd-22-1212.
Der volle Inhalt der QuelleDissertationen zum Thema "Y220C"
Jones, Rhiannon N. „Towards the design and synthesis of a p53 mutant Y220C rescue drug“. Thesis, University of Sussex, 2018. http://sro.sussex.ac.uk/id/eprint/74884/.
Der volle Inhalt der QuelleEldawra, Eliana. „Effets tératogénique et oncogénique de la mutation Trp53 Y217C“. Electronic Thesis or Diss., Sorbonne université, 2024. https://accesdistant.sorbonne-universite.fr/login?url=https://theses-intra.sorbonne-universite.fr/2024SORUS072.pdf.
Der volle Inhalt der QuelleThe TP53 gene is the most frequently mutated gene in human cancers. It is responsible for the production of the transcription factor p53, also known as the 'guardian of the genome', with diverse cellular functions and complex regulations, widely recognized today for its role in tumor suppression. My thesis focused on the study and characterization of the p53Y217C mutation in mice (corresponding to p53Y220C in humans). Most TP53 mutations affect the DNA-binding domain of the protein and are generally found at seven mutational hotspots. Of these, the Y220C mutation is of particular interest, being present in 100,000 new cases of cancer per year and in 15 cancer-prone Li-Fraumeni families. To study this mutation in vivo, we developed a mouse model expressing a p53 protein with the Y217C mutation, equivalent to Y220C in humans. Phenotypic characterization of this mouse revealed that the mutation not only deactivates the function of the protein, but also appears to confer new teratogenic and oncogenic functions
Bücher zum Thema "Y220C"
Books, Bchimak. Libro de Contabilidad Ingresos y Gastos: Libro de Cuentas Simple y Fácil de Usar para Autónomos y Cuentas Profesionales, Cuaderno de Ingresos y Gastos Simple. Y220. Independently Published, 2021.
Den vollen Inhalt der Quelle findenKonferenzberichte zum Thema "Y220C"
Dumble, Melissa, Lizhong Xu, Romyr Dominique, Binbin Liu, Hong Yang, Mary-Kate McBrayer, Dafydd Thomas et al. „Abstract LB006: PC14586: The first orally bioavailable small molecule reactivator of Y220C mutant p53 in clinical development“. In Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.am2021-lb006.
Der volle Inhalt der QuelleArowosafe, Toyin, Lucky Ishomo, Anthony Ogbebor, Esigie Benson und Rita Aigbefo. „Thru Tubing Gaslift Installation Techniques in Dual Completion for Production Optimization and Improved Recovery in Brown Field Reservoirs“. In SPE Nigeria Annual International Conference and Exhibition. SPE, 2023. http://dx.doi.org/10.2118/217476-ms.
Der volle Inhalt der Quelle